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Alternative splicing of MALT1 controls signalling
and activation of CD4þ T cells
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MALT1 channels proximal T-cell receptor (TCR) signalling to downstream signalling
pathways. With MALT1A and MALT1B two conserved splice variants exist and we
demonstrate here that MALT1 alternative splicing supports optimal T-cell activation. Inclusion
of exon7 in MALT1A facilitates the recruitment of TRAF6, which augments MALT1 scaffolding
function, but not protease activity. Naive CD4þ T cells express almost exclusively MALT1B
and MALT1A expression is induced by TCR stimulation. We identify hnRNP U as a suppressor
of exon7 inclusion. Whereas selective depletion of MALT1A impairs T-cell signalling and
activation, downregulation of hnRNP U enhances MALT1A expression and T-cell activation.
Thus, TCR-induced alternative splicing augments MALT1 scaffolding to enhance downstream
signalling and to promote optimal T-cell activation.
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A
ntigenic stimulation of the T-cell receptor (TCR) together
with a CD28 co-stimulatory receptor induces productive
activation of naive CD4þ T cells. MALT1 (mucosa-
associated lymphoid tissue protein 1) bridges TCR/CD28
co-engagement to cellular downstream signalling pathways to
promote T-cell activation and effector functions1,2. As part of the
CARMA1–BCL10–MALT1 (CBM) signalling complex, MALT1
channels upstream TCR signalling to the canonical IkB kinase
(IKK)/nuclear factor-kB (NF-kB) signalling pathway. Three
TRAF6-binding sites have been mapped on MALT1 (refs 3,4).
MALT1 recruits TRAF6 to the CBM complex to promote MALT1
ubiquitination and to facilitate activation of the IKK complex5.
Besides its scaffolding function, MALT1 contains a paracaspase
domain, and MALT1 proteolytic activity is induced on antigen
stimulation in T cells6,7. MALT1 proteolytic activity is not
directly involved in controlling canonical NF-kB signalling7,8.
However, MALT1 cleavage of the deubiquitinases A20 and
CYLD, the E3 ligase HOIL, the non-canonical NF-kB family
member RelB or the RNA regulators Regnase-1 and Roquin have
been associated with various functions for T-cell biology6,7,9–13.
Alternative splicing is a crucial and ubiquitous mechanism that
controls gene expression at the co- and post-transcriptional level.
In mammals, most pre-mRNAs are prone to alternative splicing,
which results in the generation of multiple transcripts and
proteins with diverse functions. Extensive changes in splicing
patterns have been shown to occur in the immune response and
especially in antigen-dependent T-cell activation14. Alternative
splicing can act on multiple layers ranging from cell surface
receptors, cytokines, signalling proteins to transcription factors,
and thereby constitutes an essential regulatory mechanism for
T-cell function15,16. A well-studied example is the TCR-induced
exon exclusion of the transmembrane phosphatase CD45, which
creates a negative-feedback regulation that counteracts T-cell
activation17,18. However, in T cells, little is known how alternative
splicing modulates expression and activity of intracellular
signalling mediators and how this can inﬂuence T-cell
signalling and activation.
Two conserved alternative splice isoforms of MALT1 have
been assigned that differ only by inclusion (MALT1A) or
exclusion (MALT1B) of exon7 that codes for 11 amino acids
(aa 309–319 of human MALT1). However, neither expression nor
functions of the two MALT1 alternative splice variants have been
investigated. Here we identify heterogeneous nuclear ribonucleo-
protein U (hnRNP U; SAF-A/SP120) as a factor that controls
alternative MALT1 splicing and demonstrate that TCR-induced
splicing of MALT1 increases relative MALT1A expression, which
augments MALT1 scaffolding function and fosters activation of
CD4þT cells.
Results
MALT1 exon7 supports optimal T-cell signalling and activation.
A comparison of mammalian transcriptome databases revealed
that MALT1 is expressed in two alternative splice isoforms
(Fig. 1a). The mRNA of the splice variants MALT1A (824 aa) and
MALT1B (813 aa) only differs in the inclusion or exclusion
of the 33-bp long exon7, which codes for amino acids 309–319
positioned between the Ig2- and caspase-like domains of
human MALT1. The region was shown to contain a putative
TRAF6-binding motif4. Expression of both splice variants, exon/
intron boundaries, amino-acid sequences and TRAF6-binding
site in MALT1 exon7 are highly conserved in mammals (Fig. 1a).
This evolutionary and structural conservation points to a
functional relevance of preserving the expression of the two
MALT1 variants.
Two functional TRAF6-binding motifs (T6BM2 and T6BM3)
have been identiﬁed in the C terminus of MALT1 (ref. 3; Fig. 1b).
TRAF6 binding to T6BM1 within exon7 was demonstrated, but
the role for T-cell signalling has not been investigated4. To
analyse the putative isoform-speciﬁc effects on T-cell signalling,
we generated MALT1-deﬁcient Jurkat T cells using CRISPR/Cas9
for viral reconstitution (Supplementary Fig. 1a). The absence of
MALT1 protein was veriﬁed by western blotting (Supplementary
Fig. 1b). As expected, NF-kB activation in response to PMA/
Ionomycin (P/I), but not tumour necrosis factor-a (TNF-a)
stimulation, was lost in Jurkat T-cell clone #2 that lacks MALT1
(Supplementary Fig. 1c). To analyse the differential effects of
MALT1 isoforms, MALT1-deﬁcient Jurkat T cells were
lentivirally reconstituted with MALT1A or MALT1B. Both the
isoforms were expressed at equivalent levels and in the range of
endogenous MALT1 from Jurkat T cells (Fig. 1c). Reconstitution
with either MALT1A or MALT1B rescued NF-kB signalling, but
the activation of IkBa degradation and NF-kB in MALT1A-
expressing cells was more rapid and slightly stronger when
compared with MALT1B cells (Fig. 1d), indicating that inclusion
of exon7 can facilitate TRAF6 recruitment to promote optimal
NF-kB activation.
We wanted to validate that the putative binding motif in
MALT1 exon7 is crucial for signalling in Jurkat T cells. For this,
we reconstituted MALT1-deﬁcient Jurkat T cells with MALT1A
or MALT1B constructs mutated in one or more TRAF6-binding
sites (Fig. 1b; Supplementary Fig. 1d). Whereas mutation of the
TRAF6-binding motif 2 (T6BM2) next to the Ig3 in MALT1B
does not affect signalling, activation of NF-kB, JNK and p38
completely relies on the presence of the most C-terminal T6BM3
(Supplementary Fig. 1e,f). In contrast, only the combined
mutation of T6BM1 in exon7 and the C-terminal T6BM3
(T6BM1/3 EA) in MALT1A abrogates the activation of down-
stream signalling pathways (Fig. 1e,f). To prove that the
mutations in individual or multiple T6BMs affect TRAF6
recruitment, we performed StrepT-PD of transduced Jurkat T
cells (Fig. 1g). Constitutive BCL10 association and inducible
CARMA1 recruitment were not affected by MALT1 exon7
inclusion or mutations of TRAF6 sites, but TRAF6 recruitment
was diminished in MALT1B compared with MALT1A. In line
with the effects on signalling, mutation of the binding site T6BM3
in MALT1B alone and the combined mutation of T6BM1/3 in
Figure 1 | Conserved MALT1 exon7 enhances TRAF6 recruitment and NF-jB activation but not MALT1 activity. (a) Domain structure of MALT1 isoforms
with different TRAF6-binding motifs (T6BMs) highlighted in orange and blue. Sequence conservation of T6BM1 in exon7 in different species is shown
below. Protein domains are denoted by black boxes. DD, death domain, Ig, Immunoglobulin-like domain. (b) Schematics of the T6BMs in MALT1A and
MALT1B. Different TRAF6-binding mutants were generated by glutamate (E) to alanine point mutations (A) as indicated. (c–h) MALT1-deﬁcient Jurkat
T-cell clone was reconstituted with StrepTagII (mock) or MALT1-StrepTagII variants. (c) MALT1 expression was checked by western blot (WB).
(d) Reconstituted cells were stimulated with P/I for the indicated time points. NF-kB signalling was analysed by electrophoretic mobility shift assay (EMSA)
and WB, and NF-kB signal was quantiﬁed relative to OCT1 control. (e,f) Cells transduced with MALT1A wild-type or MALT1A mutants were stimulated with
P/I for the indicated time points. NF-kB and MAPK signalling were analysed by WB and EMSA. (g) CBM complex formation as well as TRAF6 recruitment
were investigated by StrepT-PD after 30min P/I stimulation. Binding of MALT1 to NEMO was monitored after NEMO IP. Modiﬁed MALT1 indicative of
ubiquitination is marked by asterisk (*). (h) Proteins were precipitated by StrepT-PD after 20min P/I stimulation and active MALT1 was detected using
ﬂuorescent MALT1-ABP probe. Data are representative of at least three independent experiments.
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MALT1A abolished TRAF6 recruitment. Also, MALT1 ubiquitin
modiﬁcation was severely reduced only in the absences of any
functional TRAF6-binding site, which prevented recruitment of
ubiquitinated MALT1 to the IKK regulatory subunit NEMO
(Fig. 1g)5. Thus, the mutagenesis of individual or multiple
TRAF6-binding sites conﬁrms that exon7 is signiﬁcantly
contributing to the activation of downstream signalling pathways.
To test whether splicing affects MALT1 proteolytic activity in
response to T-cell stimulation, we measured MALT1 protease
activation in reconstituted Jurkat T cells using ﬂuorescently
labelled MALT1 activity-based probe (MALT1-ABP; Fig. 1h)19.
As expected, MALT1 activation was detected on P/I stimulation
and active MALT1 was heavily modiﬁed, which most likely
corresponds to previously described active MALT1 ubiquitin
conjugates20. However, MALT1A and MALT1B were activated to
a similar extent and also cleavage of the MALT1 substrate
CYLD was not altered in MALT1A- or MALT1B-expressing cells
(Supplementary Fig. 1g), revealing that MALT1 protease
activation is not affected by inclusion or exclusion of exon7.
To test whether the MALT1 splice variants exert differential
effects on CBM downstream signalling in primary T cells, we
puriﬁed CD4þ T cells from Malt1 / mice and reconstituted
the cells by retroviral transduction with either MALT1A or
MALT1B. Reconstituted T cells were expanded and transduced
cells were puriﬁed by the co-expressed surface marker Thy1.1
yielding 80–90% Thy1.1-positive T cells (Supplementary Fig. 2a).
As expected, the absence of MALT1 completely abolished NF-kB
and JNK signalling on T-cell stimulation (Supplementary
Fig. 2b)1. Expression of MALT1A and MALT1B was
comparable to endogenous MALT1 levels in T cells from wt
mice (Fig. 2a). To determine induction of NF-kB and MAPK
signalling, reconstituted T cells were restimulated with anti-CD3/
CD28 or P/I (Fig. 2b,c; Supplementary Fig. 2c,d). Expression of
both the MALT1 isoforms rescued NF-kB signalling on anti-
CD3/CD28 or P/I stimulation. Congruent with our observations
in MALT1-deﬁcient Jurkat T cells, IkBa degradation was more
rapid and NF-kB activation was stronger in cells expressing
MALT1A when compared with MALT1B. Also, JNK
phosphorylation was rescued on MALT1 expression and
MALT1A was more potent in mediating JNK activation than
MALT1B after anti-CD3/CD28 or P/I stimulation. MALT1 was
also able to rescue the partial defect in p38 activation that has
been observed earlier in MALT1-deﬁcient T cells1, but p38
activation did not rely on the MALT1 isoforms. Moreover,
despite a reduction in ERK amounts in MALT1A- or MALT1B-
expressing cells, no differences in the extent of inducible ERK
phosphorylation were detected using the two splice variants.
To investigate whether the TRAF6-binding motifs in the C
terminus and exon7 contribute to differential effects on MALT1
downstream signalling in primary T cells, we performed
reconstitutions using a series of MALT1 point mutations to
destroy T6BMs individually or in combination (Fig. 1b) and
determined the effects on NF-kB signalling in primary T cells.
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Figure 2 | MALT1A promotes stronger NF-jB and JNK activation on T-cell stimulation. (a–c) CD4þ Tcells from MALT1-deﬁcient mice (C57BL/6J) were
reconstituted with mock, MALT1A or MALT1B. (a) MALT1 expression levels of T cells from wt mice or reconstituted Malt1 / mice were determined by
western blot (WB). NF-kB (b) and MAPK signalling (c) were analysed by WB after stimulation with anti-CD3/CD28 as indicated. NF-kB DNA binding was
determined by electrophoretic mobility shift assay (EMSA). NF-kB signal was quantiﬁed relative to OCT1 control. (d,e) MALT1-deﬁcient mice (C57BL/6J)
were reconstituted with MALT1A, MALT1B or different TRAF6-binding mutants as indicated (Fig. 1b). IkBa phosphorylation and degradation were analysed
by WB after P/I stimulation and DNA binding of NF-kB was monitored by EMSA. NF-kB signal was quantiﬁed relative to OCT1 control. Data are
representative of at least three independent experiments.
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MALT1A led to a similar reduction in P/I-triggered NF-kB
signalling activation as exclusion of exon7 in MALT1B (Fig. 2d).
Moreover, NF-kB signalling was decreased on destruction of the
T6BM1 in exon7 MALT1A (T6BM1 EA; Fig. 2e). Only the
combined destruction of T6BMs in either MALT1A (T6BM1/2/3
EA) or MALT1B (T6BM2/3 EA) completely abolished the
NF-kB response (Fig. 2d,e). Thus, in primary T cells, intact
TRAF6-binding sites in the C terminus of MALT1B are sufﬁcient
to induce moderate downstream signalling, but cooperation
between C-terminal and exon7-encoded TRAF6-binding motifs
promote optimal NF-kB signalling.
In Jurkat T cells, we observed the effects of exon7 on
downstream signalling, but not on paracaspase activity, suggest-
ing that inclusion of exon7 is primarily modulating MALT1
scaffolding function. Interleukin (IL)-2 expression critically
depends on MALT1 scaffolding and partially on MALT1 cleavage
activity5,8,21–23. Indeed, IL-2 production after anti-CD3/CD28
stimulation was rescued in T cells retrovirally reconstituted with
MALT1A or MALT1B, but the number of IL-2-producing cells
was increased in MALT1A transduced cells (Fig. 3a,b). Therefore,
the stronger potency of MALT1A to promote downstream
signalling correlates with a more robust IL-2 production. TH17
differentiation was completely abolished in MALT1 protease
defective mice and is thus apparently independent of MALT1
scaffolding function22,24. To investigate whether inclusion
of exon7 inﬂuences TH17 differentiation, we adenovirally
transduced naive CD4þ T cells expressing a signalling-deﬁcient
coxsackie adenovirus receptor (CARD1) from Malt1 /R26/
CAG-CARD1stop-ﬂCd4-Cre mice12,25 using green ﬂuorescent
protein (GFP) as infection marker (Supplementary Fig. 3a). We
optimized ex vivo differentiation under TH1- or TH17-inducing
conditions and found that TH17 differentiation was absent in
Malt1 / T cells in the presence of anti-CD3 and irradiated
antigen-presenting cells (APCs; Supplementary Fig. 3b).
Interestingly, also TH1 differentiation was diminished in the
absence of MALT1, indicating that depending on the conditions
MALT1 does not only control TH17 differentiation24. Using these
conditions, we monitored the number of IFNg-producing TH1
cells and IL-17A-expressing TH17 cells in MALT1-deﬁcient cells
after viral rescue (Fig. 3c,d). Both the MALT1 splice variants
induced TH17 and TH1 differentiation to a similar extend. In
contrast, the catalytically inactive MALT1A C464A mutant was
unable to promote TH1 and TH17 differentiation. Thus, the
biochemical and functional data provide evidence that alternative
MALT1 splicing modulates MALT1 scaffolding and downstream
signalling, but does not affect MALT1 protease activity and cell
fate decisions.
TCR signalling upregulates MALT1A in CD4þ T cells. To
elucidate whether the differences in MALT1 signalling strength
observed on inclusion or skipping of exon7 are relevant for
activation of CD4þ T cells, we next investigated the expression of
MALT1 splice variants on RNA level. We designed primer pairs
that either ﬂank exon7 (ex6–ex9/10) to amplify MALT1A/B
simultaneously or exon spanning primers that selectively amplify
either MALT1A (ex5–ex7/8) or MALT1B (ex5–ex6/8; Fig. 4a,b;
Supplementary Fig. 4a). Semi-quantitative PCR (qPCR) demon-
strated that MALT1A and MALT1B are expressed at equivalent
levels in Jurkat T cells, but differentially expressed in murine

































































































































Figure 3 | MALT1A expression enhances IL-2 production but not TH17 differentiation in CD4
þ T cells. (a,b) Malt1 / CD4þ T cells were
retrovirally reconstituted with either mock, MALT1A or MALT1B. (a) Reconstituted Tcells were stimulated with anti-CD3/CD28 for 4 h and intracellular IL-2
production was analysed by FACS. (b) Quantiﬁcation of IL-2 production. The percentage of IL-2-positive cells from MALT1B-expressing cells was set to 1.
Depicted is the mean±s.d. (n¼ 3) (c,d) CD4þ T cells from Malt1 /R26/CAG-CARD1stop-ﬂCd4-Cre mice were adenovirally reconstituted with GFP
control, MALT1A, MALT1B or MALT1A C464A. Cells were cultured for 3 days under TH1- or TH17-polarizing conditions and restimulated with P/I. GFP
þ
cells were analysed for intracellular IFN-g and IL-17A levels by FACS and numbers in quadrants represent percentage of IFN-g- or IL-17A-positive cells.
(d) Data show mean±s.d. (n¼4). *Po0.05; **Po0.01; NS, not signiﬁcant; unpaired t-test.
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in murine brain and liver, the lymphoid organs spleen and thy-
mus contained almost exclusively the shorter MALT1B variant,
indicating that MALT1 is prone to alternative splicing in different
cells and tissues. To better compare MALT1 isoform expression,
we ampliﬁed either MALT1A or MALT1B by qPCR. In murine
CD4þ T cells, MALT1B transcripts were more abundant and
expressed B100-fold more than MALT1A mRNA, which was
hardly detectable (Fig. 4c). Next, we analysed the changes in
mRNA expression of the two MALT1 isoforms after TCR/CD28
stimulation by semi-qPCR or qPCR (Fig. 4d–f). Again, MALT1A
transcripts in CD4þ T cells puriﬁed from spleen or thymus were
almost undetectable, but MALT1A was induced by a factor of 10–
12 on anti-CD3/CD28 or anti-CD3 stimulation. P/I stimulation
was not sufﬁcient to induce MALT1A, suggesting that proximal
TCR signalling events are critical. MALT1B levels were only
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Figure 4 | TCR ligation induces MALT1 splicing and exon7 inclusion in CD4þ T cells. (a) Scheme of MALT1 primers amplifying MALT1A (ex5–ex7/8),
MALT1B (ex5–ex6/8) or MALT1A/B (ex6–ex9/10 or ex16–ex17). (b) Analysis of MALT1 mRNA levels by RT–PCR in Jurkat T cells and different murine
tissues from BALB/c mice using ex6–ex9/10 primers amplifying both isoforms. GAPDH served as control. (c–f) MALT1A and MALT1B mRNA levels in
CD4þ T cells from BALB/c mice were investigated by qPCR (c,f) or semi-qPCR (d,e) using isoform-speciﬁc ex5–ex7/8 or ex5–ex6/8 primers. Transcript
levels were normalized to Hydroxymethylbilane Synthase (HMBS) mRNA levels. For semi-qPCR, ampliﬁcation cycles were adjusted for MALT1A (35 cycles)
and MALT1B (28 cycles). (g) MALT1A and MALT1B mRNA levels were analysed in OT-II CD4þ T cells cultured for 6 h alone or with irradiated wild-type
APCs unloaded or loaded with 1 mgml 1 OVA peptide. HMBS served as internal control and relative induction was determined comparative to unloaded
APCs cultured with OT-II T cells. (h) Activated CD62LCD44þ effector memory T cells, naive CD62LþCD44 T cells and CXCR5þPD1þ T-follicular
helper (TFH) cells were sorted from immunized BALB/c mice. RNA was isolated, and MALT1A and MALT1B levels were analysed by semi-qPCR using
isoform-speciﬁc primer pairs. (i) CD4þ T cells from BALB/c and C57BL/6J mice were treated with anti-CD3, anti-CD28 or both stimuli. After lysis,
MALT1A was precipitated using anti-MALT1A antibody. A pan-MALT1 antibody was used for detection by western blot (WB). (j) Primary human CD4þ T
cells from four donors were stimulated with anti-CD3/CD28 for 3 h. MALT1A and MALT1B mRNA levels were measured by qPCR using human MALT1A- or
MALT1B-speciﬁc primers. RP2 served as internal control and relative induction was determined comparative to unstimulated cells. Data are representative
for two (b,d) or three (c,e–i) or four (j) independent experiments. Depicted is the mean±s.d. (c,e–i; n¼ 3) or (j; n¼4). *Po0.05; **Po0.01; ***Po0.001;
NS, not signiﬁcant; unpaired t-test.
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ligation, which was also seen for overall MALT1 expression
(Supplementary Fig. 4b). Induction of MALT1A, but not
MALT1B expression, was also observed on stimulation of pri-
mary OT-II T cells with the ovalbumin (OVA) peptide-loaded
APCs (Fig. 4g). Thus, TCR ligation induces alternative MALT1
splicing and inclusion of exon7. Despite the higher expression of
MALT1B, TCR signalling triggers a relative increase of MALT1A
transcript levels in CD4þ T cells.
To conﬁrm that the induction of MALT1A was also seen in vivo,
BALB/c mice were immunized by intravenous injection of sheep
erythrocytes. After 7 days, naive T cells (CD62LþCD44 ),
activated effector memory T cells (CD62L-CD44þ ) and T-follicular
helper cells (TFH; CXCR5þPD1þ ) were puriﬁed. Whereas
MALT1B transcripts were not changed in the three T-cell subsets,
the MALT1A splice variant was highly expressed in activated T cells
and TFH cells, but low in naive T cells (Fig. 4h). Thus, alternative
MALT1 splicing is also induced in vivo, leading to a MALT1A
upregulation in activated CD4þ T-cell subsets.
To address whether TCR-induced alternative splicing and
exon7 inclusion also enhanced MALT1A protein amounts,
we generated a rabbit polyclonal antibody against exon7 (aa
309–316), which is identical in human and murine MALT1A. On
overexpression of MALT1, the antibody recognized exclusively
Flag-MALT1A in western blots or after immunoprecipitation (IP)
and did not cross-react with Flag-MALT1B (Supplementary
Fig. 4c). To detect endogenous MALT1A, we had to enrich
MALT1A by IP and used the higher afﬁnity pan-MALT1
antibody for immunoblot detection (Fig. 4i). MALT1A protein
was hardly detectable in CD4þ T cells, but anti-CD3/CD28
stimulation induced MALT1A expression in T cells from different
mouse strains. Again, anti-CD3 stimulation alone was able to
induce MALT1A expression. Owing to the high MALT1B
expression levels, total MALT1 protein expression was largely
unchanged after stimulation and we only observed a modest
upregulation in C57BL/6 mice. Taken together, the results
demonstrate that TCR ligation leads to an alteration in the
MALT1 isoform ratio and an increase in the relative amounts of
MALT1A in activated T cells.
Since MALT1 exon7 is conserved in mammals, we asked
whether differences in MALT1A and MALT1B levels are also
seen in human T cells puriﬁed from peripheral blood. Human
CD4þ T cells expressed more MALT1B mRNA compared with
MALT1A (Fig. 4j). Again, anti-CD3/CD28 stimulation induced a
relative increase in MALT1A expression. Even though the effects
were not as pronounced as in splenic murine CD4þ T cells, the
data reveal that MALT1 is prone to alternative splicing in human
T cells.
hnRNP U negatively regulates inclusion of MALT1 exon7. To
corroborate our ﬁndings that MALT1 is prone to alternative
splicing, we searched for RNA-binding proteins that inﬂuence the
relative expression of MALT1A and MALT1B. Since both the
MALT1 isoforms are expressed constitutively in Jurkat T cells
(Fig. 4a), we initiated two independent small interfering RNA
(siRNA) screens after transfection of smart pool siRNA against
putative RNA-binding proteins that have been connected to
splicing. We determined relative expression of MALT1A and
MALT1B either by qPCR (Fig. 5a) or radioactive PCR
(Supplementary Fig. 5a; Supplementary Table 1). In both data
sets, we identiﬁed the splice factor hnRNP U as a candidate that
induced the most robust inclusion of MALT1 exon7 and thus the
strongest shift towards the MALT1A expression. Knockdown of
hnRNP U by the smart pool siRNA was veriﬁed by qPCR and
MALT1 exon7 inclusion was also evident by semi-qPCR
(Supplementary Fig. 5b,c). Next, we conﬁrmed the relative
increase in the expression levels of MALT1A versus MALT1B
using three independent siRNAs (Fig. 5b,c). Thus, RNA inter-
ference identiﬁed hnRNP U as a negative regulator of exon7
inclusion in Jurkat T cells.
To validate the impact of hnRNP U, we investigated binding of
hnRNP U to the MALT1 pre-mRNA. RNA-binding protein IP
(RIP) was performed with anti-hnRNP U or IgG control
antibodies in Jurkat T cells and the MALT1 pre-mRNA near
exon7 (between exon6 and exon9) or in a more distant region
(exon2) was ampliﬁed by qPCR (Fig. 5d). The pre-mRNA of
MALT1 in the region of exon7 was enriched on hnRNP U RIP
and highest values were obtained for the fragments in proximity
or covering exon7. Speciﬁcity was conﬁrmed by hnRNP U
knockdown and ampliﬁcation of an in1–ex2 fragment, which was
not enriched after hnRNP U RIP. hnRNP U association to
MALT1 pre-mRNA was also seen in semi-qPCR using
in6/ex7–in7 primers (Supplementary Fig. 5d). To address
whether cis-regulatory sequences around exon7 are able to
control skipping or inclusion, we constructed a minigene bearing
exon7 and ﬂanking intronic sequences cloned between constitu-
tive exon3 and 7 of CD45. Whereas Jurkat T cells transfected with
the longer construct M2 resulted in equivalent exon7 skipping/
inclusion, exon7 was almost completely excluded using the
shorter fragment M1 (Fig. 5e). hnRNP U induced exon7
exclusion in both minigenes conﬁrming its role as a negative
regulator of exon7 splicing. Thus, our data reveal that enhancer
and silencer regions in the vicinity to exon7 control alternative
MALT1 splicing and that binding of hnRNP U impairs exon7
inclusion.
To determine whether hnRNP U is also controlling MALT1A
transcript levels on TCR stimulation in primary T cells, we used
adenoviral small hairpin RNA (shRNA) knockdown in murine
CD4þ T cells. Infected CD4þ T cells were sorted based on
co-expression of GFP and an efﬁcient downregulation of hnRNP
U was obtained with two independent shRNAs (Fig. 5f;
Supplementary Fig. 5e). Indeed, increased MALT1A expression
after anti-CD3 stimulation was detected after downregulation of
hnRNP U (Fig. 5g). In contrast, MALT1B expression was not
altered. We asked whether enhanced MALT1A expression might
be correlated with a decrease in hnRNP U after T-cell activation.
However, on RNA level, the MALT1A suppressor hnRNP U was
induced, but at the same time other splicing factors that enhanced
MALT1A in the screens (for example, hnRNP R, SRSF3
and SRSF9) were increased (Supplementary Fig. 5f). Thus,
TCR-induced alternative splicing of exon7 and the relative
expression of MALT1A/B transcripts in CD4þ T cells is
regulated by hnRNP U, but alternative MALT1 splicing seems
to be regulated by a complex network of negatively and positively
acting splice factors.
MALT1A supports and hnRNP U counteracts T-cell activation.
To test a potential inﬂuence of alternative MALT1 splicing on
cellular signalling in T cells, we designed a morpholino oligomer
(MO) targeting the exon7–intron7 boundary of the MALT1
pre-mRNA to selectively prevent alternative inclusion of exon7
and thus MALT1A expression (Fig. 6a). MALT1A MO (AMO)
suppressed MALT1A mRNA and protein expression in mouse
embryonic ﬁbroblasts (MEFs; Supplementary Fig. 6a,b). Also, in
murine T cells, AMO treatment abolished anti-CD3- or anti-
CD3/CD28-stimulated induction of MALT1A transcripts without
affecting transcript levels of MALT1B (Fig. 6b,c; Supplementary
Fig. 6c).
Since freshly isolated CD4þ T cells lack considerable
MALT1A expression, no changes in NF-kB signalling and JNK
activation were observed in AMO-treated cells stimulated with
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anti-CD3/CD28 or P/I (Supplementary Fig. 6d,e). To test whether
induction of MALT1A on TCR ligation can augment T-cell
signalling, we pretreated CD4þ T cells with anti-CD3 to induce
MALT1A expression and restimulated the cells with P/I, taking
advantage of the fact that P/I bypasses upstream TCR stimulation
that may be altered due to the prestimulation. NF-kB was
enhanced after 4 h TCR prestimulation, and the activation of
NF-kB and JNK was augmented on secondary P/I restimulation,
while the activities of ERK and p38 were unaffected in these
experimental conditions (Fig. 6d,e). To test whether MALT1A
induction is required to augment NF-kB and JNK signalling on
restimulation, we cultured the puriﬁed CD4þ T cells in the
presence of AMO during anti-CD3 pretreatment to prevent









































































































200 bp 197 bp
506 bp 539 bp
M1
M2































































































































Figure 5 | Splice factor hnRNP U counteracts exon7 inclusion and MALT1A expression in T cells. (a) Identiﬁcation of RNA-binding proteins involved in
MALT1 splicing by RNA interference. Jurkat T cells were transfected with smart pool siRNA against the depicted proteins and the ratio MALT1A/B mRNA
was analysed by qPCR. (b) Knockdown of hnRNP U after transfection of three independent siRNAs in Jurkat T cells. (c) qPCR of MALT1A and MALT1B
mRNA after downregulation of hnRNP U in Jurkat Tcells. Shown is the MALT1A/B mRNA ratio. (d) Binding of hnRNP U to MALT1 pre-mRNA. IgG control IP
or anti-hnRNP U IP was carried out from extracts of si-control- or si-hnRNP U-transfected Jurkat T cells. IP of MALT1 pre-mRNA was detected by qPCR
using primers amplifying the depicted fragments. Primers amplifying MALT1 pre-mRNA in1–ex2 served as negative control. (e) Exon7 spanning minigenes
M1 and M2 were transfected into Jurkat T cells together with si-control or si-hnRNP U. Transcript levels of the minigene with or without exon7 were
analysed by RT–PCR. (f) hnRNP U knockdown on mRNA level in CD4þ Tcells after transduction of either control or two hnRNP U adenoviruses. hnRNP U
levels were analysed by qPCR using sorted GFPþ CD4þ T cells after 6 h anti-CD3/CD28 stimulation. (g) Analysis of MALT1A and MALT1B transcript
levels after 6 h anti-CD3/CD28 stimulation of either control or sh-hnRNP U-transduced cells. All qPCR were performed using HMBS as internal control.
Data are representative for two (a,d) or three (b,c,e–g) independent experiments. Depicted is the mean±s.d. (a,d; n¼ 2) or (c,f,g; n¼ 3). *Po0.05;
**Po0.01; ***Po0.001; NS, not signiﬁcant; unpaired t-test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11292
8 NATURE COMMUNICATIONS | 7:11292 | DOI: 10.1038/ncomms11292 | www.nature.com/naturecommunications
NF-kB activation and slightly enhanced JNK phosphorylation on
secondary P/I stimulation in untreated or in cMO-treated T cells
(Fig. 6f,g). In contrast, inhibition of MALT1A by AMO severely
reduced NF-kB activation and mildly impaired JNK signalling.
Both the pathways are activated after AMO treatment to a similar
degree as in CD4þ T cells without prestimulation. Again, ERK
and p38 activation were not affected, revealing that MALT1A
induction is selectively affecting NF-kB and JNK signalling. Since
JNK activation in Jurkat T cells has been linked to CYLD cleavage
by MALT1 paracaspase10, we checked for changes in MALT1
paracaspase activity and CYLD cleavage in primary T cells
depending on the induction of MALT1A (Fig. 6h; Supplementary


















































































































1.0 20 13 24 27 54 2.6 10 18 18 62 74 Fold induction NF-κB
Figure 6 | Induction of MALT1A augments T-cell signalling. (a) Scheme for vivo morpholino (MO)-induced disruption of MALT1A expression. MO is
designed to bind the 30-splice site of exon7/intron7 in MALT1 pre-mRNA to prevent spliceosomal recognition. (b,c) CD4þ Tcells from BALB/c mice were
treated with morpholino against MALT1A (AMO), control MO (cMO) or kept untreated for 18 h before anti-CD3 or anti-CD3/CD28 stimulation for 6 h.
MALT1 mRNA levels were analysed by qPCR using isoform-speciﬁc primers. HMBS served as internal control and relative induction was determined
by comparing stimulated to unstimulated cells. (d,e) CD4þ T cells from BALB/c mice were pretreated with anti-CD3 for 4 h and afterwards stimulated
with P/I for the indicated times. Phosphorylation and degradation of IkBa (d) as well as MAPK activation (e) were analysed by WB. Electrophoretic mobility
shift assay (EMSA) was used to detect DNA binding of NF-kB (d). (f–h) Untreated, AMO- or cMO-treated CD4þ T cells were pretreated with anti-CD3
(4 h) before stimulation with P/I. (f,g) NF-kB and MAPK signalling were analysed by EMSA and WB. NF-kB signal was quantiﬁed relative to OCT1 control.
(h) CYLD cleavage was monitored by WB. Data are representative of two (h) or three independent experiments (b–g). In b and c, the mean±s.d. (n¼ 3) is
depicted.
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Fig. 6f). Inhibition of MALT1A induction did not alter MALT1
protease activation. CYLD cleavage was reduced after anti-CD3
pretreatment, but morpholino treatment did not alter CYLD
cleavage after P/I restimulation, revealing that augmented JNK
signalling is not caused by enhanced MALT1 activity.
In Malt1 / T cells, expression of MALT1A promoted
a more robust T-cell signalling and IL-2 production when
compared with MALT1B (Figs 2 and 3). To test whether
MALT1A induction is also required for robust T-cell activation,
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CD3/CD28 for 6 h and surface expression of activation markers
CD25 and CD69 as well as induction of IL-2 were examined.
Indeed, prevention of MALT1A induction led to reduced surface
expression of CD69 and CD25 (Fig. 7a,b). Further, induction of
IL-2 mRNA as well as the number of IL-2-expressing cells were
decreased in AMO-treated CD4þ T cells (Fig. 7c-e), reﬂecting
that TCR-triggered induction of MALT1A is necessary to
promote optimal T-cell activation.
To provide evidence that alternative splicing and MALT1A
induction is involved in augmented T-cell activation, we
determined the effects of knocking down the splicing factor
hnRNP U that counteracts inducible MALT1A production in
CD4þ T cells (Fig. 5g). Indeed, CD25 surface expression was
signiﬁcantly enhanced in GFPþ cells containing the adenoviral
hnRNP U shRNA, but not in the GFP cells (Fig. 7f–h).
The weaker differences in CD69 upregulation after hnRNP U
knockdown is most likely due to the rapid localization of
intracellular CD69 at the cell surface on T-cell activation26.
We sorted GFP expressing CD4þ T cells to determine IL-2
expression on mRNA and protein level. Again, sh-hnRNP U
augmented IL-2 induction and enhanced the number of
IL-2-expressing cells (Fig. 7i,j). Taken together, prevention or
enhancement of MALT1A induction by morpholinos or
sh-hnRNP U, respectively, exerted opposing effects on T cell
activation, suggesting that MALT1 alternative splicing controls
relative MALT1A and MALT1B levels and thus functions as a
molecular switch to tune T-cell activation.
Discussion
MALT1 paracaspase controls adaptive and innate immune
signalling pathways and is a key regulator of T-cell activation27.
Despite the fact that two conserved MALT1 splice variants exist
in mammals neither expression nor the functional relevance of
these MALT1 isoforms has been explored. Here we show that
MALT1 is prone to alternative splicing. While murine CD4þ
T cells express almost exclusively the shorter isoform MALT1B,
the longer exon7 containing variant MALT1A is induced on TCR
stimulation. Lower MALT1A expression and induction of
MALT1A after T-cell stimulation was also observed in human
CD4þ T cells from peripheral blood. We ﬁnd differences in the
levels of MALT1A/B in human and murine cells, but
the different sources, puriﬁcation protocols and stimulatory
conditions preclude a quantitative comparison. We identiﬁed the
RNA-binding protein hnRNP U as a negative regulator of exon7
inclusion in human Jurkat and murine primary T cells and we
show that MALT1A upregulation enhances T-cell signalling and
activation. Despite the induction of MALT1A, MALT1B
remained the more abundant isoform, suggesting that not the
absolute amounts, but the shifted balance in MALT1A versus
MALT1B expression is deﬁning downstream effects. The
relevance of MALT1 alternative splicing is also underscored by
the observation that MALT1A transcripts are elevated in vivo in
T cells with a more activated phenotype such as effector memory
T cells and TFH cells.
Alternative splicing is an important mechanism regulating cell
function during the immune response14. Global analysis of
splicing events using exon array demonstrated extensive
alternative exon usage in many immune regulators during
T-cell activation28. Alternative exon7 usage of MALT1 in
T cells was never reported using exon arrays, most likely
because the short exon7 cannot be detected in global analyses.
TCR-induced inclusion of exon7 generates the hyperactive
MALT1A isoform that provides an additional and functional
TRAF6-binding motif that boosts NF-kB activation and slightly
enhances JNK signalling in primary T cells. Also, in Jurkat T cells
MALT1A was slightly more effective in triggering downstream
signalling, but interestingly deletion of exon7 in MALT1B exerted
a more severe effect than point mutation of T6BM1, suggesting
that the role of exon7 may not be restricted to TRAF6
recruitment. Further, whereas in Jurkat T cells one of two
T6BMs was largely sufﬁcient to trigger full-NF-kB signalling,
decreased signalling was seen after mutation of individual sites in
CD4þ T cells. Thus, modulation of signalling strength by
alternative MALT1 splicing seems to be more important in
primary T cells, presumably to enhance weaker TCR signals.
Constitutively expressed MALT1B seems to function as a
molecular rheostat that limits the signalling strength in naive
CD4þ T cells and MALT1A induction in activated T cells is
required to overcome a threshold and to achieve a full response.
Thus, we propose that TCR-induced MALT1 splicing is part of a
positive feed-forward mechanism that is tuning T-cell signalling
to allow productive T-cell activation.
MALT1 acts as a molecular scaffold protein to recruit the IKK
complex to the CBM complex5, but it is also a protease which is
activated on T-cell stimulation6,7. Since exon7 contains a
functional TRAF6-binding site and TRAF6-dependent MALT1
ubiquitination drives NF-kB signalling5, the data suggest that
exon7 inclusion augments MALT1 scaffolding. The E3 ligase
TRAF6 can catalyse MALT1 poly-ubiquitination and trigger IKK
activation3,5, but its role in T-cell activation has been questioned
as TRAF6 ablation does not signiﬁcantly affect TCR signalling to
NF-kB and MAPK29. Nevertheless, our mutagenesis underscores
an essential requirement of the TRAF6-binding motifs for
MALT1 scaffolding function, suggesting that another E3 ligase
may compensate for the loss of TRAF6. Clearly, inclusion of
exon7 in MALT1A does not enhance protease function, which is
in line with the results obtained by comparing Malt1 / and
MALT1 paracaspase mutant (Malt1PM) mice21–23,30. CD4þ
T cells from both Malt1 / and Malt1PM mice are unable to
differentiate into TH17 cells22,24. Congruently, we show in
reconstitution experiments in vitro that catalytically inactive
Figure 7 | MALT1A induction and hnRNP U downregulation augment T-cell activation. (a–e) CD4þ Tcells from BALB/c mice were left untreated or were
treated with AMO or cMO before stimulation. (a) Cell surface expression of CD69 and CD25 was determined by FACS after 6 h of anti-CD3/CD28
stimulation. (b) Mean ﬂuorescence intensity (MFI) values of CD25 and CD69 after stimulation of MO-treated cells. (c) Induction of IL-2 mRNA in CD4þ
T cell (no MO, AMO or cMO treated) after anti-CD3/CD28 stimulation was determined by qPCR. (d) Intracellular IL-2 staining after anti-CD3/CD28
and different MO treatments was analysed by FACS. (e) Number of IL-2-positive cells as gated in d was quantiﬁed in relation to stimulated control cells
(no MO). (f–j) CD4þ T cells from R26/CAG-CARD1stop-ﬂCd4-Cre mice were transduced with control or sh-hnRNP U adenoviruses and stimulated with
anti-CD3/CD28. (f) Cells gated for GFPlow and GFPhigh expression (left) were analysed for CD25 and CD69 surface expression (right). (g,h) CD25 and
CD69 MFI values after stimulation of adenoviral-transduced cells. MFI was directly compared between GFPlow (no hnRNP U knockdown)- and GFPhigh
(hnRNP U knockdown)-expressing cells. (i) Relative IL-2 mRNA levels in sorted GFPþ CD4þ T cell on adenoviral transduction of control or sh-hnRNP
U #1 after anti-CD3/CD28 stimulation was determined by qPCR. (j) Intracellular IL-2 levels after anti-CD3/CD28 stimulation in sorted GFPþ cells was
analysed by FACS. Histograms and dot blots show representatives of two (j) or three (a–i) independent experiments. (b,c,e,g–i) Depicted is the mean±s.d.
(n¼ 3). *Po0.05; **Po0.01; ***Po0.001; NS, not signiﬁcant; unpaired t-test.
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MALT1 does not promote TH17 development, but both MALT1
splice variants support TH17 differentiation. Further, our data
indicate that even though TH1 differentiation is not completely
relying on MALT1, the catalytic activity augments TH1
development. Thus, differentiation processes are apparently
primarily driven by MALT1 protease function, which is
required to remove the critical post-transcriptional regulators
Roquin and Regnase-1 that counteract upregulation of TH17
differentiation factors such as IkBz or IkBNS12,31–33. In contrast,
proteolytic activity of MALT1 is largely dispensable for direct
downstream signalling to NF-kB and JNK21,22,30, providing
further evidence that the differential effects of MALT1 splice
variants are caused by the scaffolding function. JNK activation
has been connected to MALT1-catalysed CYLD cleavage10.
However, MALT1 activity and CYLD cleavage were not affected
by blocking MALT1A induction and JNK activation was also not
impaired in T cells from Malt1PM mice21,22,30, revealing that JNK
signalling in naive CD4þ T cells is not relying on MALT1
protease activity. Thus, biochemical and functional evidence
demonstrates that alternative splicing modulates MALT1
scaffolding function, but not protease activity.
We identiﬁed several RNA-binding factors that inﬂuence
splicing of MALT1 by either promoting inclusion (for example,
hnRNP R, hnRNP LL and SRSF3) or skipping (for example,
hnRNP H1, hnRNP A1, U2AF1 and hnRNP U) of exon7.
Together with a minigene approach, the results indicate that
MALT1 exon7 splicing is controlled by a complex machinery of
positive and negative trans-acting factors as well as cis-acting
RNA elements. In the screen, we identiﬁed hnRNP U as the most
potent negative regulator of exon7 inclusion in Jurkat T cells.
hnRNP U knockdown enhanced TCR-induced upregulation of
MALT1A and T-cell activation, supporting the conclusion that
alternative splicing of MALT1 modulates T-cell responses.
hnRNP U is able to bind DNA and RNA, and it has been
implicated in a variety of biological processes. Recent genome-
wide studies revealed that hnRNP U is an important regulator of
alternative splicing34,35. hnRNP U can promote exon skipping or
inclusion in a highly context-dependent manner and it can act in
conjunction with other splicing regulators. Since the initial search
already indicated that multiple RNA-binding proteins impact on
alternative MALT1 splicing, it seems reasonable to assume that
MALT1A and MALT1B levels will be regulated by a network of
splice factors. TCR stimulation induces the expression of hnRNP
U, but at the same time putative MALT1A promoting splice
factors such as hnRNP R, SRSF3 and SRSF9 are increased,
suggesting that expression and competition of a complex network
of positive and negative splice factors may control MALT1
splicing. Clearly, a more detailed understanding about these
factors and their cis-acting elements is required to elucidate the
mechanism how TCR signalling impacts on MALT1 splicing.
hnRNP U was suggested to regulate splice site selection either by
modulating the core splicing machinery or by directly targeting
the pre-mRNA35,36. The processes are not mutually exclusive and
future studies must determine the exact mechanism how hnRNP
U regulates exon7 splicing of MALT1. Little is known how
cellular signalling pathways inﬂuence splicing. AKT signalling
was shown to control hnRNP U- and hnRNP L-dependent
Caspase-9 splicing36. Recently, JNK signalling was shown to
induce alternative splicing of multiple targets including the MAP
kinase kinase 7 (MKK7) upon T-cell activation37. It will be
interesting to unravel if similar molecular mechanisms link TCR
stimulation to MALT1 splicing.
We show that alternative MALT1 splicing impacts on
signalling strength and induction of the hyperactive splice variant
MALT1A pushes more robust T-cell activation. Such positive
feed-forward regulation may facilitate to surpass thresholds for
cellular decisions and they even can take place on the single-cell
level. Thus, the relative MALT1A and MALT1B expression may
trigger different programs in individual cells. Interestingly,
intrinsic characteristics of T-cell signalling determine the fate of
naive CD4þ T cells38. Strong TCR signalling favours TFH over
TH1 development, but the underlying molecular mechanisms that
translates the magnitude of TCR signalling into a response
remains elusive. We ﬁnd that induced MALT1 splicing augments
TCR signalling to NF-kB and JNK, and that MALT1A expression
in vivo is indeed high in TFH cells. We propose that MALT1
alternative splicing constitutes an early bifurcation point to
translate TCR signalling into different T-cell activation states that
may favour distinct fate decisions and effector functions in an
immune response.
Methods
Mice. C57BL/6 mice were from Jackson laboratory and BALB/c as well as OT-II
(C57BL/6Tg(TcraTcrb)425Cbn/Crl) mice were from Charles River. Malt1 / and
Malt1 /R26/CAG-CARD1stop-ﬂCd4-Cre mice (C57BL/6 genetic background)
were described1,25. All experiments were performed using 8–16-week-old
(C57BL/6, BALB/c, OT-II) or 10–30-week-old (Malt1 / and Malt1 /
R26/CAG-CARD1stop-ﬂCd4-Cre) male or female mice. All mice were housed in
accordance with institutional guidelines. Immunization was done in accordance
with established guidelines of the Regional Ethics Committee of Bavaria and animal
protocols were approved by local authorities.
Antibodies and reagents. The following antibodies were used for stimulation,
ﬂuorescence-activated cell sorting FACS) staining and western blot and IP:
anti-CD3 (145-2C11), anti-CD28 (37.51), Streptavidin-PE, anti-CXCR5 (RF8B2,
unconjugated) and anti-NEMO (Clone 54; western blot; all from BD Biosciences);
anti-Thy1.1-APC (HIS51), anti-IL-2-FITC or anti-IL-2-APC (JES6-5H4), anti-
CD25-PE (PC61.5), anti-CD69-APC (H1.2F3), anti-CD2-APC (RPA-2.10),
anti-TCR-b-Biotin (H57-597), anti-CD4-PerCP (RM4-5) and anti-PD-1-FITC
(J43; all from eBioscience); anti-BCL10 (EP606Y), biotinylated goat anti-rat IgG,
anti-hnRNP U (3G6) and anti-TRAF6 (EP591Y; all from Abcam); anti-CD62L-
AlexaFluor 647 (MEL-14; from Biolegend); anti-CD44-AlexaFluor 405 (IM7;
Caltag); anti-MALT1 (B12), anti-MALT1 (H300), anti-b-Actin (I-19), anti-p38 (C-
20), anti-CYLD (E10) and anti-NEMO (FL-419; IP; all from Santa Cruz
Biotechnology); anti-CARMA1 (1D12), anti-MALT1 (2494), anti-p-ERK (9101),
anti-p-p38 (9211), anti-p-JNK (9255), anti-p-IkBa (9246), anti-IkBa (L35A5),
anti-JNK (9252) (all from Cell signalling); anti-ERK (442704; Calbiochem);
rabbit anti-syrian hamster IgG (dianova) and anti-Flag-M2 (from Sigma-Aldrich);
horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson
ImmunoResearch); and rabbit polyclonal antibody was raised against peptide
GRTDEAVEC from MALT1A. For differentiation experiments, the following
antibodies, reagents and cytokines were used: anti-CD3 (145-2C11), anti-CD28
(37N), anti-IL-12 (C17.8), anti-IL-4 (11B11), anti-IFN-g (Xmg1.2) and
anti-CD16/32 (2.4G2; produced by V.H. and E. Kremmer); anti-mIL-2 (JES6-5H4;
Miltenyi); anti-CD45.2-APC-Cy7 (30-F11), anti-CD4-PE-Cy7 (GK1.5),
anti-IFN-g-APC (XMG1.2), anti-IL-17A-PE (eBio17B7; all from eBioscience);
indol-1 for live/dead-cell viability assays (Life Technologies); recombinant mouse
IL-12 (BD Biosciences) and recombinant mouse IL-6 and TGF-b (R&D Systems).
The following reagents were used: recombinant human TNF-a (Biomol); Phorbol
12-myristate 13-acetate (PMA/P) and ionomycin (Iono/I; both from Calbiochem);
murine anti-CD3/CD28 coated beads (anti-CD3: 13.3 mgml 1; anti-CD28:
26.6 mgml 1; Life Technologies); human T-Activator CD3/CD28 Dynabeads
(Life Technologies); Protein G Sepharose (GE Healthcare); Strep-Tactin Sepharose
(IBA); brefeldin-A (Sigma); OVA peptide (aa 323–339; ISQAVHAAHAEINEAGR;
Biotrend), LumiGlo reagent (Cell Signaling), vivo-MOs: AMO, GAACCAAAGGA
TTGCACTACCTTCA and standard control (cMO), CCTCTTACCTCAGTTACA
ATTTATA (both from GeneTools). For siRNA knockdown experiments, the
following siRNAs and shRNAs were used: ON-TARGETplus SMARTpool siRNA
library (qPCR) and siGENOME SMARTpool siRNA library (radioactive PCR;
all from Dharmacon). ON-TARGETplus Non-targeting pool (si-control) and
ON-TARGETplus SMARTpool si-hnRNP U were used for further knockdown
experiments. For veriﬁcation of the SMARTpool effects, the following individual
siRNAs were used: siRNA negative control (si-control), si-hnRNP U #1: 50-ACA
GAAAGGCGGAGAUAAAUU-30 , si-hnRNP U #2: 50-GAAGAAAGAUUGUGA
AGUUUU-30 ; si-hnRNP U #3: GAUGAAGACUAUAAGCAAAUU (all
Eurogentec). For adenoviral knockdown experiments, shRNAs directed against
hnRNP U (sh-hnRNP U #1: 50-CCATAACTGTGCAGTTGAATT-30, sh-hnRNP U
#2: 50-GGCTGGTCACTAACCACAAGT-30) and adenoviral control virus were
purchased from Sirion Biotech. The following oligonucleotides were used for
electrophoretic mobility shift assays: H2K (forward: 50-GATCCAGGGCTGGGGA
TTCCCCATCTCCACAGG-30 , reverse: 50- GATCCCTGTGGAGATGGGGAAT
CCCCAGCCCTG-30), OCT1 (forward: 50- GATCTGTCGAATGCAAATCACTA
GAA-30 , reverse: 50-GATCTTCTAGTGATTTGCATTCGACA-30).
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Cell culture and stimulation. Jurkat T cells were cultured in RPMI 1640
medium (Life Technologies) supplemented with 10% FCS and 100Uml 1
penicillin/streptomycin (P/S, Life Technologies). Stimulation of Jurkat T cells was
initiated by the addition of Phorbol 12-myristate 13-acetate (PMA) (200 ngml 1)
and ionomycin (300 ngml 1) or TNF-a (10 ngml 1). DMEM with 10% FCS,
100Uml 1 P/S and 50mM b-mercaptoethanol (Life Technologies) was used for
culture of Phoenix packaging cells. Human embryonic kidney (HEK) 293 cells and
MEFs were cultured in DMEM with 10% FCS and 100Uml 1 P/S. For retroviral
reconstitution experiments, CD4þ T cells from spleen and lymph nodes were
isolated using mouse CD4þ T-cell-speciﬁc Dynabeads (Life Technologies). Dif-
ferentiation experiments were performed using the naive CD4þ T-cell isolation kit
(Miltenyi). For other experiments, isolation of murine CD4þ T cells was per-
formed by negative magnetic-activated cell sorting (MACS) selection using the
CD4þ T-cell isolation kit II (Miltenyi). Primary T cells were cultured in RPMI
medium supplemented with 10% heat-inactivated FCS, 1% P/S, 1% NEAA (Life
Technologies), 1% HEPES, 1% L-glutamine, 1% sodium pyruvate (Life Technolo-
gies) and 0.1% b-mercaptoethanol. CD4þ T cells were stimulated with anti-CD3
(0.5mgml 1) and anti-CD28 (1 mgml 1) on plates precoated with rabbit anti-
hamster IgG or anti-CD3/CD28-coated beads (3:1) or with PMA (30 ngml 1) and
ionomycin (300 ngml 1). To analyse the isoform-speciﬁc effects regarding TH1
and TH17 differentiation, infected naive CD4þ T cells (0.2 106) were stimulated
with anti-CD3 (1 mgml 1) and irradiated APCs (2 106) from CD45.1 mouse
(T:APC ratio is 1:10) in TH1 and TH17 culture conditions: TH1, IL-12 (10 ngml 1)
and anti-IL-4 (10mgml 1); TH17, TGF-b (10mgml 1), IL-6 (60 ngml 1), anti-
IL-12 (10 mgml 1), anti-IL-4 (10 mgml 1), anti-IFN-g (5 mgml 1) and anti-IL-2
(2.5mgml 1). Cells were cultured for 72 h until restimulation with PMA (20 nM)
and ionomycin (1mM) for 4 h. For restimulation, cells were washed twice with PBS
and were incubated for 4 h with PMA (20 nM) and ionomycin (1 mM). To analyse
differences in surface marker expression after adenoviral knockdown, cells
(0.1–0.5 106) were stimulated using anti-CD3 precoated 96-well plates
(0.5mgml 1) and soluble anti-CD28 (1 mgml 1). To determine MALT1 splicing
in CD4þ T cells from OT-II mice, APCs were prepared from spleen and lymph
node cells of wild-type mice and depleted for TCR-bþ T cells (using anti-TCR-b-
Biotin). After irradiation (2,000 rad), APCs (2 106) were pulsed with 1 mgml 1
OVA peptide (aa 323–339) for 1 h at 37 C, washed with PBS and subsequently
incubated with OT-II CD4þ T cells (2 106) in a ratio 1:1 for 6 h before being
lysed in RNA lysis buffer. Human CD4þ T cells were isolated from peripheral
blood by negative MACS selection (Miltenyi), cultured in advanced RPMI 1640
medium supplemented with 10% heat-inactivated FCS and 2mM L-glutamine (Life
Technologies), and stimulated (2 106) with human T-Activator CD3/CD28
Dynabeads (Life Technologies). Written consent and approval by the ethics board
of the Medical Faculty at the Technical University Munich was obtained for the use
of peripheral blood from healthy donors.
Generation and reconstitution of MALT1-deﬁcient T cells. Bicistronic expres-
sion vector px330 expressing Cas9 and sgRNA39,40 was digested with BbsI and the
linearized vector was gel puriﬁed. A pair of oligos (50-CCGTGGTCCAGATATAT
AGC-30 and 50-GGTTGAAGCAAATGCAATGC-30) for each targeting site was
annealed and ligated to the linearized vector. Jurkat T cells (2.5 106) were
electroporated (220V and 1,000mA (Gene pulser X, Bio-Rad) with px330 plasmids
expressing sgRNA targeting both the sides of the exon2 of the MALT1 gene as well
as plasmid bearing a puromycin selection cassette. At 24 h after electroporation,
puromycin (2 mgml 1) was added and taken off after 48 h. Isolation of clonal cell
lines was achieved by serial dilutions and was followed by an appropriate expansion
period. Cell clones were genotyped using PCR with intronic primers ﬂanking both
the sides of exon 2. MALT1 expression in exon2-deleted cells was analysed by
western blot. For reconstitution, MALT1 isoforms were linked to Flag-Strep-Strep
tag and hDCD2 by a co-translational processing site T2A41 and introduced
into pHAGE plasmids. Lentivirus was produced by transfecting sub-conﬂuent
HEK293T cells with 1.5 mg PAX, 1 mg pMD2G and 2 mg transfer vector. After
72 h, lentivirus was collected, ﬁltered and Jurkat T cells (0.5 106 cells) were
infected in the presence of 8 mgml 1 polybrene. After 24 h, virus was replaced
with RPMI medium. After 1 week in culture, FACS analysis revealed 495%
DCD2-positive cells.
Retroviral and adenoviral transduction of CD4þ T cells. Retroviruses were
produced in Phoenix cells transfected with pMSCV plasmids carrying human
Flag-MALT1 constructs and Thy1.1 (separated by internal ribosome entry site
(IRES) sequence) and viruses were collected after 48 and 72 h. For retroviral
reconstitution, CD4þ T cells from Malt1 al mice were simulated with plate-
bound anti-CD3/anti-CD28 for 48 h and afterwards infected with retroviral
supernatant supplemented with Polybrene (8mgml 1). After 6-h incubation, cells
were resuspended in media supplemented with 20Uml 1 IL-2 and expanded for
another 72 h. Thy1.1-positive cells were puriﬁed by MACS (Miltenyi) yielding
populations of B90% Thy1.1-positive T cells. Cells were then restimulated with
plate-bound anti-CD3/anti-CD28 or P/I.
For T-cell differentiation experiments, full-length MALT1A, MALT1B or
MALT1A C464A mutant were cloned in the pCAGAdDu-IRES-eGFP vector.
HEK293A cells (1 105) were transfected with 3 mg linearized plasmids using
jetPEI reagent (Polyplus transfection). When all cells show cytopathic effects,
cells were detached and primary virus was collected by three freeze–thaw cycles.
Primary virus was ampliﬁed in HEK293A cells using an multiplicity of infection
(MOI) of 50 and virus lysate was collected by freeze–thaw cycles after cytopathic
effect. For adenoviral knockdown, adenoviruses encoding control or sh-hnRNP U
#1 and #2 (identiﬁed above) were purchased from Sirion Biotech and ampliﬁed in
HEK293A cells (200 ml). Virus was titrated using A549 cells. For differentiation
experiments, naive CD4þ T cells from Malt1 /R26/CAG-CARD1stop-ﬂCd4-Cre
mice were transduced with GFP control, MALT1A, MALT1B or MALT1A C464A
virus using an MOI of 50. CD4þ T cells from R26/CAG-CARD1stop-ﬂCd4-Cre
mice were infected with control or sh-hnRNP U virus (MOI of 50). After 5 h of
infection, cells were washed twice with PBS, resuspended in primary T-cell medium
and rested for 40 h before sorting of GFPþ CD4þ T cells using FACS Star PLUS
(BD) and stimulation. Transduction efﬁciency was determined by FACS. T-cell
differentiation experiments were conducted as indicated above.
Cell lysis and IP. For analysis of expression levels or activation of signalling
pathways, cells (1–5 106) were lysed in high-salt buffer (20mM HEPES (pH 7.9),
350mM NaCl, 20% glycerol, 1mM MgCl2, 0.5mM EDTA, 0.1mM EGTA, 1% NP-
40, 1mM dithiothreitol (DTT), 10mM sodium ﬂuoride, 8mM b-glycerophosphate,
300 mM sodium vanadate and protease inhibitor cocktail). For binding studies,
cells (1–5 107) were lysed in co-IP buffer (25mM HEPES (pH 7.5), 150mM
NaCl, 0.2% NP-40, 10% glycerol, 1mM DTT, 10mM sodium ﬂuoride, 8mM
b-glycerophosphate, 300 mM sodium vanadate and protease inhibitor cocktail).
Lysate controls were mixed with 4 SDS-loading dye and boiled. IP was carried
out using antibodies against NEMO (9 ml) or MALT1A (15 ml) overnight at 4 C.
After antibody incubation, Protein G Sepharose (20ml 1:1 suspension) was added
and incubated for 1–2 h at 4 C. For Strep-tagged proteins, precipitation was
performed using Strep-Tactin Sepharose (30 ml 1:1 suspension) at 4 C overnight.
Beads were washed with co-IP buffer and boiled after addition of 20 ml 2
SDS-loading dye. Lysates and IPs were separated by SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and analysed by western blot.
Western blot. Proteins were transferred onto polyvinylidene diﬂuoride
membranes for immunodetection using electrophoretic semi-dry transfer system.
After transfer, membranes were blocked with 3% bovine serum albumin (BSA) for
1 h at room temperature and incubated with speciﬁc primary antibody (indicated
above, dilution 1:1,000 in 1.5% BSA/PBS-T) overnight at 4 C. Membranes were
washed in PBS-T before addition of HRP-coupled secondary antibodies (indicated
above, 1:7,000 in 0.75% BSA in PBS-T; 1 h, room temperature). HRP was detected
by enhanced chemiluminescence using the LumiGlo reagent (Cell Signaling)
according to the manufacturer’s instructions. Images have been cropped for
presentation. Full-size images are presented in Supplementary Fig. 7.
Electrophoretic mobility shift assay. For electrophoretic mobility shift assays,
double-stranded NF-kB or OCT1-binding sequences (H2K or OCT1 see reagents)
were labelled with [a-32P] dATP using Klenow Fragment (NEB). To monitor
DNA binding, whole-cell lysates (3–6 mg) were incubated for 30min at room
temperature with shift-buffer (HEPES (pH 7.9; 20mM), KCl (120mM), Ficoll
(4%)), DTT (5mM), BSA (10 mg) and poly-dI-dC (2 mg, Roche), and radioactive
probe (10,000–20,000 c.p.m.). Samples were separated on a 5% polyacrylamide gel
in TBE buffer, vacuum-dried and exposed to autoradiography. To determine
NF-kB fold induction, intensities of NF-kB bands were quantiﬁed relative to
OCT1 signal using ImageJ software. Images have been cropped for presentation.
Full-size images are presented in Supplementary Fig. 7.
Flow cytometry. For surface protein staining, unspeciﬁc binding was blocked with
anti-CD16/32 (dilution 1:50) in FACS buffer (PBS with 2% FCS and 0.01% sodium
azide) and cells were stained with monoclonal antibodies (dilution 1:100).
For intracellular IL-2 staining, cells (0.5–1 106) were stimulated for 6 h with
anti-CD3/anti-CD28 in the presence of brefeldin-A (10 ngml 1, Sigma) for 3 h
before staining. Dead cells were excluded with ethidium monoazide bromide
(dilution 1:100). Cells were ﬁxed in 2% paraformaldehyde and permeabilized
in PBS/0.5% Saponin/1% BSA. Unspeciﬁc binding was blocked with mouse
anti-CD16/32 (dilution 1:50) and staining was performed with corresponding
antibodies (indicated above, dilution 1:100). For T-cell differentiation experiments,
cells were stimulated for 4 h with PMA (20 nM) and ionomycin (1 mM) in the
presence of brefeldin-A for 2 h before staining. Afterwards, ﬁxable dead-cell
staining (indol-1) was performed for 30min at 4 C, followed by surface staining
(anti-CD45.2, anti-CD4; dilution 1:200). Cells were ﬁxed for 10min at 20 C with
4% paraformaldehyde and were permeabilized for 20min at 4 C in PBS/0.5%
Saponin/1% BSA. The cells were then stained for 50min at 4 C with antibodies
detecting IL-17A and IFNg (dilution 1:200 each). Samples were acquired on LSRII
or LSR Fortessa (BD) or Attune Acoustic Focusing Cytometer (Life Technologies)
and analysed with FlowJo software (Tree Star).
Immunization and isolation of different T-cell subsets. For isolation of different
T-cell subsets, BALB/c mice were immunized intravenous with B2 108 sheep
erythrocytes (Acila AG, Mo¨rfelden, Germany). After 1 week, the spleens were
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collected and single-cell suspensions prepared. To enrich for T cells, B cells were
depleted using anti-CD19 microbeads (Miltenyi) according to the manual. Cells
were then stained using following antibodies and reagents for 20min on ice:
anti-CXCR5, biotinylated goat anti-rat IgG, Streptavidin-PE, anti-CD4-PerCP,
anti-PD-1-FITC, anti-CD62L-AlexaFluor 647 and anti-CD44-AlexaFluor 405.
After washing, different T-cell subsets (CD4þCD62LþCD44 naive T cells,
CD4þCD62LCD44þ effector T cells and CD4þCXCR5þPD1þ TFH cells)
were sorted on a FACS Aria cell sorter (BD) and subsequently lysed in Trizol
for RNA extraction.
MALT1 activity detection using MALT1-ABPs. MALT1-ABPs (6 and 7)
have been described previously19. To investigate MALT1 activity of different
MALT1-Strep constructs, Jurkat T cells (2–5 107) were lysed in 900 ml co-IP
buffer, centrifuged (14,000 r.p.m., 4 C, 10min) and overexpressed MALT1-Strep
constructs were precipitated using Strep-Tactin Sepharose. After three washing
steps with co-IP buffer, bead-bound MALT1-Strep was incubated with 3 mM
ﬂuorescent MALT1-ABP (probe 6: BODIPY-LRSR-AOMK) for 1 h at 30 C, mixed
with 4 loading dye and boiled. Proteins were separated by SDS–PAGE and
ﬂuorescence was detected by a Typhoon Scanner (FITC laser 488 nm/ﬁlter 526 SP).
A plate assay enzyme-linked activity sorbent assay was used to detect active
MALT1 in primary CD4þ T cells. Cells (1 107) were lysed in 200ml co-IP buffer,
centrifuged (14,000g, 4 C, 10min) and extract was incubated with 0.1 mM
biotinylated MALT1-ABP (probe 7: BIOTIN-KLRSR-AOMK). Extract was
transferred to streptavidin-coated plates (Thermo Scientiﬁc) and incubated
overnight at 4 C. After washing in PBS-T (0.05% Tween-20) and blocking with 2%
BSA in PBS-T, detection was performed by incubation with MALT1 primary
antibody (1:800 in 1% BSA in PBS-T; 1 h, room temperature) and HRP-coupled
secondary antibody (1:1,500 in 1% BSA in PBS-T; 1 h, room temperature). Three to
ﬁve washing steps with PBS-T were used after antibody incubation. Luminescence
was determined after 3,30 ,5,50-Tetramethylbenzidin (TMB) substrate incubation for
10–20min and subsequent stop reaction with 1M H2SO4 in a photometer (Bio-
Tek) at 450 and 570 nm.
Cell transfection. Transfection of HEK293 cells with pEF Flag-MALT1 plasmids
(2mg) was performed by calcium phosphate transfection. For knockdown experi-
ments using vivo morpholinos, CD4þ T cells (3 106) or MEFs (0.5 106) were
transfected with 5 nmol of AMO or cMO and cultured for 3 h (RNA) or 18 h
(protein). After MO transfection, primary T cells were stimulated with either
plate-bound or bead-coupled anti-CD3/CD28 or P/I. Knockdown efﬁciency was
determined by qPCR. For siRNA knockdown, Jurkat T cells were transfected
with 100 nM siRNA and Atufect transfection reagent (0.5–1 mgml 1; Silence
Therapeutics) and analysed after 72 h. For minigene analysis, after 48 h of siRNA-
transfecion, Jurkat T cells (2.5 106) were electroporated with 1 mg minigene 1
(M1) or 2 (M2) using 220V and 1,000mA (Gene pulser X, Bio-Rad), cultivated for
24 h and subsequently lysed in protein or RNA lysis buffer. For siRNA screen using
radioactive PCR, 1 106 Jurkat T cells were transfected with siRNA (10 pmol, from
siGenome SMARTpool) using the Amaxa Nucleofector and the manufacture’s
protocol for Jurkat T cells. RNA was analysed 60 h post transfection.
RNA-binding protein IP and minigene. RIP was performed using the Magna RIP
kit (Merck Millipore) according to the manual. Puriﬁed RNA was analysed by
qPCR. RIP RNA fractions were normalized to the corresponding RNA input
fractions and calculated relative to IgG control (IgG control set as 1). For the
minigene assay, genomic MALT1 region for M1 and M2 were ampliﬁed by PCR
from human genomic clone pBACe3.6 (Source BioScience) and cloned between
constant CD45 exons (exon3 and exon7) in a minigene vector42. After transfection
(as indicated above), RNA was isolated and reverse transcribed. To analyse MALT1
exon7 inclusion or exclusion of M1 and M2, two speciﬁc vector backbone primers
(CD45 exon3 forward and CD45 exon7 reverse) were used to amplify alternatively
spliced minigene products. RP2 levels served as internal control. PCR primers are
listed in Supplementary Table 2 and 3.
RNA preparation and qPCR. RNA was isolated (Qiagen RNeasy Kit) with
subsequent DNase treatment (Promega) and reverse transcribed (Verso cDNA
synthesis kit, Thermo Fisher). For qPCR, a LightCycler 480 from Roche was
used with LightCycler SYBR Green I Master Mix. Semi-qPCR was performed
using DreamTaq Polymerase (Thermo Fisher). For siRNA screen using MALT1
splicing-sensitive radioactive PCR, RNA was analysed with primers in ﬂanking
constant exons (ex6 and ex9/10). Products were analysed by denaturing PAGE
and Phosphoimager quantiﬁcation. PCR primers are listed in Supplementary
Table 2 and 3.
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